OSF is a chronic progressive scarring oral disease typically affecting Asians. It is characterised by a burning sensation, blanching and stiffening of the oral mucosa and, in the advanced stages, the jaws may become inseparable with resultant difficulty in eating, swallowing, speech and maintenance of oral health. What makes it more sinister is its potential for malignant transformation, with the reported risk ranging from 2.3-7.6%. 1, 2 Scientific literature to date provides firm evidence that areca nut use is the major aetiological factor but the exact mechanism of areca nut constituents' action on the oral mucosal tissue remains unknown. Nevertheless, most studies propose increased collagen Study selection Meta-analyses, randomised controlled trials (RCT), clinical trials and other experimental designs were considered.
more sinister is its potential for malignant transformation, with the reported risk ranging from 2.3-7.6%. 1, 2 Scientific literature to date provides firm evidence that areca nut use is the major aetiological factor but the exact mechanism of areca nut constituents' action on the oral mucosal tissue remains unknown. Nevertheless, most studies propose increased collagen synthesis and reduced degradation by various pathways as the likely pathogenesis. This knowledge has enabled the development of numerous therapeutic strategies which are broadly categorised into surgical and nonsurgical (ie, drugs and physiotherapy) approaches and are employed according to the severity of lesions. 3 This review focuses on the drug management of this enigmatic disease and has identified all the pertinent studies. The drugs used to date includes steroids, fibrinolytic enzymes, anti-ischemic Results Seventeen publications were identified of which 15 were included. Of these, six were RCT, four were clinical trials/ controlled clinical trials, and five were other types experimental studies. The studies in total involved 1224 patients. The rate of those lost to followup reached 30% in some studies. The drugs used to treat oral submucous fibrosis (OSF) were categorised into steroids, enzymes, cardiovascular drugs, antioxidants, vitamins and microelements.
Conclusions There are few high-quality studies available and the present drug treatments are in general empirical and treat only symptoms. There is a need for high-quality RCT in this area, especially studies involving combined and sequential therapy.
